{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:08:11Z","timestamp":1793117291492,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1208\/s12248-013-9554-7","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T17:42:37Z","timestamp":1386870157000},"page":"172-180","source":"Crossref","is-referenced-by-count":79,"title":["Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination"],"prefix":"10.1208","volume":"16","author":[{"given":"Donna A.","family":"Volpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salaheldin S.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei K.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"9554_CR1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1208\/s12248-008-9068-x","volume":"10","author":"PV Balimane","year":"2008","unstructured":"Balimane PV, Marino A, Chong S. P-gp inhibition potential in cell-based models: which \u201ccalculation\u201d method is the most accurate? AAPS J. 2008;10:577\u201386.","journal-title":"AAPS J"},{"key":"9554_CR2","unstructured":"Food and Drug Administration (2012). Draft guidance. Guidance for industry: drug interaction studies\u2014study design, data analysis, and implications for dosing and labeling. Available from http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm064982.htm . Accessed 28 October 2013."},{"key":"9554_CR3","unstructured":"European Medicine Agency. Guideline on the investigation of drug interactions. 2012. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500129606&mid=WC0b01ac058009a3dc . Accessed 28 October 2013."},{"key":"9554_CR4","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s12272-011-1107-y","volume":"34","author":"HK Han","year":"2011","unstructured":"Han HK. Role of transporters in drug interactions. Arch Pharmacol Res. 2011;34:1865\u201377.","journal-title":"Arch Pharmacol Res."},{"key":"9554_CR5","doi-asserted-by":"crossref","unstructured":"Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006; 8(1):article 1.","DOI":"10.1208\/aapsj080101"},{"key":"9554_CR6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejps.2005.11.011","volume":"27","author":"JP Keogh","year":"2006","unstructured":"Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug\u2013drug interactions involving P-glycoprotein. Eur J Pharm Sci. 2006;27:543\u201354.","journal-title":"Eur J Pharm Sci"},{"key":"9554_CR7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1023\/A:1018877803319","volume":"16","author":"RB Kim","year":"1999","unstructured":"Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationships between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408\u201314.","journal-title":"Pharm Res"},{"key":"9554_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","volume":"299","author":"JW Polli","year":"2001","unstructured":"Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001;299:620\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"9554_CR9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejps.2005.07.013","volume":"26","author":"A Collett","year":"2005","unstructured":"Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci. 2005;26:386\u201393.","journal-title":"Eur J Pharm Sci"},{"key":"9554_CR10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/jps.21010","volume":"97","author":"DA Volpe","year":"2008","unstructured":"Volpe DA. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J Pharm Sci. 2008;97:712\u201325.","journal-title":"J Pharm Sci"},{"key":"9554_CR11","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.105.005421","volume":"33","author":"ME Taub","year":"2005","unstructured":"Taub ME, Podila L, Ely D, Almeida I. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos. 2005;33:1679\u201387.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1124\/dmd.112.050500","volume":"41","author":"J Bentz","year":"2013","unstructured":"Bentz J, O\u2019Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, et al. Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin DDI risk assessment decision criteria. Drug Metab Dispos. 2013;41:1347\u201366.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR13","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1002\/jps.22652","volume":"100","author":"H Sugimoto","year":"2011","unstructured":"Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, et al. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci. 2011;100:4013\u201323.","journal-title":"J Pharm Sci"},{"key":"9554_CR14","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1080\/00498250802499467","volume":"38","author":"JS Taur","year":"2008","unstructured":"Taur JS, Rodriguez-Proteau R. Effects of dietary flavonoids on the transport of cimetidine via P-glycoprotein and cationic transporters in Caco-2 and LLC-PK1 cell models. Xenobiotica. 2008;38:1536\u201350.","journal-title":"Xenobiotica"},{"key":"9554_CR15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/00498250802017715","volume":"38","author":"L Zhang","year":"2008","unstructured":"Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica. 2008;38:709\u201324.","journal-title":"Xenobiotica"},{"key":"9554_CR16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","volume":"11","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zhang Y, Zhao P, Huang SM. Predicting drug\u2013drug interactions: an FDA perspective. AAPS J. 2009;11:300\u20136.","journal-title":"AAPS J"},{"key":"9554_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/clpt.2008.195","volume":"85","author":"KS Fenner","year":"2009","unstructured":"Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro\u2013in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85:173\u201381.","journal-title":"Clin Pharmacol Ther"},{"key":"9554_CR18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1124\/dmd.105.008615","volume":"34","author":"J Rautio","year":"2006","unstructured":"Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006;34:786\u201392.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/mp900174z","volume":"7","author":"JA Cook","year":"2010","unstructured":"Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, et al. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]\/IC50 and [I]2\/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm. 2010;7:398\u2013411.","journal-title":"Mol Pharm"},{"key":"9554_CR20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"9554_CR21","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1161\/01.CIR.0000132482.95686.87","volume":"109","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Adams KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109:2959\u201364.","journal-title":"Circulation"},{"key":"9554_CR22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1248\/bpb.24.403","volume":"24","author":"T Nakamura","year":"2001","unstructured":"Nakamura T, Kakumoto M, Yamashita K, Takara K, Tanigawara Y, Sakaeda T, et al. Factors influencing the prediction of steady state concentrations of digoxin. Biol Pharm Bull. 2001;24:403\u20138.","journal-title":"Biol Pharm Bull"},{"key":"9554_CR23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/clpt.1984.141","volume":"36","author":"PE Fenster","year":"1984","unstructured":"Fenster PE, Hager WD, Goodman MM. Digoxin\u2013quinidine\u2013spironolactone interaction. Clin Pharmacol Ther. 1984;36:70\u20133.","journal-title":"Clin Pharmacol Ther"},{"key":"9554_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00314854","volume":"42","author":"A Hedman","year":"1992","unstructured":"Hedman A, Angelin B, Arvidsson A, Dahlqvist R. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol. 1992;42:481\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"9554_CR25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cpt1978242162","volume":"24","author":"S Waldorff","year":"1978","unstructured":"Waldorff S, Andersen JD, Heeb\u00f8ll-Nielsen N, Nielsen OG, Moltke E, S\u00f8rensen U, et al. Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther. 1978;24:162\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"9554_CR26","doi-asserted-by":"crossref","first-page":"F84","DOI":"10.1152\/ajprenal.1999.277.1.F84","volume":"277","author":"S Ito","year":"1999","unstructured":"Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G. Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol Renal Physiol. 1999;277:F84\u201396.","journal-title":"Am J Physiol Renal Physiol."},{"key":"9554_CR27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1592\/phco.23.4.436.32125","volume":"23","author":"CS Karyekar","year":"2003","unstructured":"Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model. Pharmacother. 2003;23:436\u201342.","journal-title":"Pharmacother."},{"key":"9554_CR28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1248\/bpb.22.1355","volume":"22","author":"K Takara","year":"1999","unstructured":"Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999;22:1355\u20139.","journal-title":"Biol Pharm Bull"},{"key":"9554_CR29","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","volume":"26","author":"AH Saad","year":"2006","unstructured":"Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730\u201344.","journal-title":"Pharmacotherapy"},{"key":"9554_CR30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","volume":"30","author":"E Dodds-Ashley","year":"2010","unstructured":"Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy. 2010;30:842\u201354.","journal-title":"Pharmacotherapy"},{"key":"9554_CR31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-199712000-00001","volume":"19","author":"KM Jalava","year":"1997","unstructured":"Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit. 1997;19:609\u201313.","journal-title":"Ther Drug Monit"},{"key":"9554_CR32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0773.1996.tb00273.x","volume":"79","author":"J Partanen","year":"1996","unstructured":"Partanen J, Jalava KM, Neuvonen PJ. Itraconazole increases serum digoxin concentration. Pharmacol Toxicol. 1996;79:274\u20136.","journal-title":"Pharmacol Toxicol"},{"key":"9554_CR33","doi-asserted-by":"crossref","first-page":"e19329","DOI":"10.1371\/journal.pone.0019329","volume":"6","author":"PR Ding","year":"2011","unstructured":"Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1\/P-glycoprotein transporter. PLoS One. 2011;6:e19329.","journal-title":"PLoS One"},{"key":"9554_CR34","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1158\/0008-5472.CAN-11-0375","volume":"71","author":"Z Shi","year":"2011","unstructured":"Shi Z, Tiwari AK, Patel AS, Fu LW, Chen ZS. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res. 2011;71:3735\u20138.","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"9554_CR35","first-page":"S49","volume":"85","author":"D Jian-Wei","year":"2009","unstructured":"Jian-Wei D, Song I, Shon J, Shin J. Characterization of efflux transport of PDE5 inhibitors, sildenafil, vardenafil, and udenafil. Clin Pharmacol Ther. 2009;85 Suppl 1:S49.","journal-title":"Clin Pharmacol Ther"},{"key":"9554_CR36","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.2042-7158.2012.01498.x","volume":"64","author":"MK Choi","year":"2012","unstructured":"Choi MK, Song IS. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil. J Pharm Pharmacol. 2012;64:1074\u201383.","journal-title":"J Pharm Pharmacol"},{"key":"9554_CR37","first-page":"1254","volume":"21","author":"G Rohde","year":"2001","unstructured":"Rohde G, Bauer R-J, Unger S, Ahr G, Wensing G. Vardenafil, a new selective PDE5 inhibitor, produces no interaction with digoxin. Pharmacotherapy. 2001;21:1254.","journal-title":"Pharmacotherapy"},{"key":"9554_CR38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1023\/A:1016140429238","volume":"19","author":"F Tang","year":"2002","unstructured":"Tang F, Horie K, Borchardt RT. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002;19:765\u201372.","journal-title":"Pharm Res"},{"key":"9554_CR39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/00498254.2011.587033","volume":"41","author":"H Glavinas","year":"2011","unstructured":"Glavinas H, von Richter O, Vojnits K, Mehn D, Nagy T, Janossy J, et al. Calcein assay: a high-throughput method to assess P-gp inhibition. Xenobiotica. 2011;41:712\u20139.","journal-title":"Xenobiotica"},{"key":"9554_CR40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejpb.2007.03.017","volume":"67","author":"S Siissalo","year":"2007","unstructured":"Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortej\u00e4rvi H, Urtti A, et al. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm. 2007;67:548\u201354.","journal-title":"Eur J Pharm Biopharm"},{"key":"9554_CR41","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/dmd.109.027490","volume":"37","author":"E Kamiyama","year":"2009","unstructured":"Kamiyama E, Sugiyama D, Nakai D, Miura S, Okazaki O. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. Drug Metab Dipos. 2009;37:1956\u201362.","journal-title":"Drug Metab Dipos."},{"key":"9554_CR42","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/jps.23069","volume":"101","author":"K Mease","year":"2012","unstructured":"Mease K, Sane R, Podila L, Taub ME. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012;101:1888\u201397.","journal-title":"J Pharm Sci"},{"key":"9554_CR43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s13318-011-0046-9","volume":"36","author":"AG Patil","year":"2011","unstructured":"Patil AG, D\u2019Souza R, Dixit N, Damre A. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. Eur J Drug Metab Pharmacokinet. 2011;36:115\u20139.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"9554_CR44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jps.21114","volume":"97","author":"Y Shirasaka","year":"2008","unstructured":"Shirasaka Y, Sakane T, Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2008;97:553\u201365.","journal-title":"J Pharm Sci"},{"key":"9554_CR45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejps.2008.08.004","volume":"35","author":"R Hayeshi","year":"2008","unstructured":"Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci. 2008;35:383\u201396.","journal-title":"Eur J Pharm Sci"},{"key":"9554_CR46","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.111.038075","volume":"39","author":"J Li","year":"2011","unstructured":"Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011;39:1196\u2013202.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1124\/dmd.109.029967","volume":"38","author":"M Darnell","year":"2010","unstructured":"Darnell M, Karlsson JE, Owen A, Hidalgo IJ, Li J, Zhang W, et al. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. Drug Metab Dispos. 2010;38:491\u20137.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR48","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/00498250802050880","volume":"38","author":"R Elsby","year":"2008","unstructured":"Elsby R, Surry DD, Smith VN, Gray AJ. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica. 2008;38:1140\u201364.","journal-title":"Xenobiotica"},{"key":"9554_CR49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lfs.2009.11.006","volume":"86","author":"E Kamiyama","year":"2010","unstructured":"Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci. 2010;86:52\u20138.","journal-title":"Life Sci"},{"key":"9554_CR50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.110.035881","volume":"39","author":"R Elsby","year":"2011","unstructured":"Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011;39:275\u201382.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 2","key":"9554_CR51","first-page":"193","volume":"43","author":"ES Perloff","year":"2011","unstructured":"Perloff ES, Mason AK, Kapadnis S, Khun W, Fox LG, Stresser DM. Comparison of digoxin efflux inhibition in Caco-2 and MDR1-LLC-PK1 cell monolayers. Drug Metab Rev. 2011;43 Suppl 2:193.","journal-title":"Drug Metab Rev"},{"key":"9554_CR52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00003088-200746120-00004","volume":"46","author":"S Eberl","year":"2007","unstructured":"Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, K\u00f6nig J, et al. Role of P-glycoprotein inhibition for drug interactions evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46:1039\u201349.","journal-title":"Clin Pharmacokinet"},{"key":"9554_CR53","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15144-6","volume":"28","author":"EF Choo","year":"2000","unstructured":"Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28:655\u201360.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00210-008-0345-0","volume":"379","author":"O Richter von","year":"2009","unstructured":"von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn-Schmied Arch Pharmacol. 2009;379:11\u201326.","journal-title":"Naunyn-Schmied Arch Pharmacol."},{"key":"9554_CR55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1124\/dmd.107.018176","volume":"36","author":"P Hsiao","year":"2008","unstructured":"Hsiao P, Bui T, Ho RJY, Unadkat JD. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood\u2013brain barrier. Drug Metab Dispos. 2008;36:481\u20134.","journal-title":"Drug Metab Dispos"},{"key":"9554_CR56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/dmd.105.007377","volume":"34","author":"J Weiss","year":"2006","unstructured":"Weiss J, Haefeli WE. Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: F 2 values. Drug Metab Dispos. 2006;34:203\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 3","key":"9554_CR57","first-page":"76","volume":"41","author":"J Lin","year":"2009","unstructured":"Lin J, Grimm S. IC50 determinations in an in vitro P-glycoprotein inhibition assay: P app values vs. efflux ratios. Drug Metab Rev. 2009;41 Suppl 3:76.","journal-title":"Drug Metab Rev"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-013-9554-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-013-9554-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-013-9554-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T04:37:19Z","timestamp":1746074239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-013-9554-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,13]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["9554"],"URL":"https:\/\/doi.org\/10.1208\/s12248-013-9554-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,13]]}}}